An interventional study of stomach-partitioning gastrojejunostomy and conventional gastrojejunostomy in Gastric Cancer and Gastric Outlet Obstruction, sponsored by Guangxi Medical University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Guangxi Medical University · Not applicable, Interventional, and Treatment
Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (GO-PART Study, KLASS 16)
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,183 studies in Stomach Neoplasms with a site in China — 480 open to participants now, 556 under way, 50 of them phase 3. Stomach Neoplasms · China.
Among the 1,183 studies in Stomach Neoplasms with a site in China, this one is the 453rd largest by planned enrollment of the 880 interventional ones that give a count, is one of 92 that started in 2026, is one of 221 with no phase, reaches primary completion later than 508 of the 555 other live ones, and was the 1,124th registered.
3,401 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →480 of the 1,183 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:
Hua Huang, MD, PhD · Sites in China
Ages 18–70
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Akeso · Sites in China, United States, Germany and 1 more country
Ages 18+
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Jie Yuan，MD · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 167 · Phase 2 420 · Phase 3 146 · Phase 4 24
First in 1997; this study’s year is marked. 92 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 87 across the 880 interventional studies, 300 across the 303 observational. Of the 270 that completed or were terminated, 28 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 1,183 have an industry lead sponsor. The 10 most frequent:
Guangxi Medical University is the lead sponsor of 71 studies on the registry; 14 are open to participants now.
Guangxi Medical University has 2 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
124 of the studies in Stomach Neoplasms with a site in China that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06221748Phase 3RemeGen Co., Ltd.DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | 2026-12 |
| NCT05918094Phase 3Sun Yat-sen UniversityComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | 2026-12 |
| NCT06939439Phase 3The First Affiliated Hospital with Nanjing Medical UniversityUsing ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | 2026-12-31 |
| NCT06177041Phase 3FutureGen Biopharmaceutical (Beijing) Co., LtdM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. | 2027-01-11 |
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
Add all 124 to your calendar (.ics) → With an account.
Among the 1,183 studies in Stomach Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gastric outlet obstruction (GOO) complicates locally advanced or metastatic gastric cancer and severely impairs oral intake, nutritional status, and quality of life. Conventional gastrojejunostomy (CGJ) effectively relieves the obstruction but is associated with a high incidence of delayed gastric emptying (DGE), which delays the resumption of oral intake and the initiation of systemic anticancer therapy. Stomach-partitioning gastrojejunostomy (SPGJ) isolates the tumour-bearing distal stomach from the alimentary tract and has been suggested, in retrospective studies, to reduce the incidence of DGE. However, the only randomized comparison reported to date was a small monocentric trial that assessed oral intake acceptance rather than gastric emptying. The comparative effect of SPGJ and CGJ on delayed gastric emptying therefore remains untested in a randomized setting. This multicenter, randomized, open-label, blinded-outcome-assessment trial will randomly assign 80 participants with unresectable distal gastric adenocarcinoma complicated by GOO, in a 1:1 ratio, to undergo either SPGJ or CGJ. The primary endpoint is the incidence of postoperative DGE within 30 days after surgery.
This is a prospective, multicenter, randomized, open-label superiority trial with blinded outcome assessment, conducted at three tertiary referral hospitals in Guangxi, China (Guangxi Medical University Cancer Hospital, Wuzhou Red Cross Hospital, and Guangxi Medical University Wuming Hospital). The coordinating center is Guangxi Medical University Cancer Hospital.
Eligible participants will be randomly assigned in a 1:1 ratio to undergo either stomach-partitioning gastrojejunostomy (SPGJ) or conventional gastrojejunostomy (CGJ), using a computer-generated allocation sequence with variable block sizes, stratified by participating centre. The allocation sequence will be generated centrally by an independent statistician and implemented through a centralized, password-protected randomization system. Allocation will remain concealed until eligibility has been confirmed and written informed consent has been obtained.
Surgical procedures cannot be blinded. Outcome assessors (including the radiologist assessing the primary endpoint), research staff collecting patient-reported outcomes, and the statistician performing the prespecified analyses will be blinded to treatment allocation.
In both groups, a laparoscopic approach will be preferred and routine diagnostic laparoscopy will be performed to confirm surgical eligibility. Gastrointestinal reconstruction will use a standardized isoperistaltic configuration; Braun enteroenterostomy and Roux-en-Y reconstruction will not be performed.
In the SPGJ group, partial gastric transection will be performed using a linear cutting stapler, beginning at the greater curvature, at the junction of the gastric body and antrum or approximately 5 cm proximal to the superior margin of the tumour, preserving a 2-3 cm-wide gastric channel along the lesser curvature. A side-to-side gastrojejunostomy will be constructed between the posterior wall of the proximal gastric segment at the greater curvature and the antimesenteric border of the jejunum 5-10 cm distal to the ligament of Treitz, via an antecolic route. The common enterotomy will be closed with a linear stapler or hand-sewn sutures.
In the CGJ group, a side-to-side gastrojejunostomy will be constructed via an antecolic route between the most dependent portion of the greater curvature of the stomach and the proximal jejunum 5-10 cm distal to the ligament of Treitz. The common enterotomy will be closed with a linear stapler or hand-sewn sutures.
Both groups will receive a standardized perioperative management protocol. Participants will be assessed daily for DGE-related signs from postoperative day (POD) 1 to POD 7, with formal DGE assessments on POD 3, 7, 14 and 21, and a further assessment at the 30-day postoperative visit. After the 30-day safety visit, follow-up will be performed every 3 months. A prespecified analysis of overall survival will be performed at 12 months after surgery.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo laparoscopic stomach-partitioning gastrojejunostomy. The gastric body is partially transected with a linear cutting stapler, beginning at the greater curvature, at the junction of the gastric body and antrum or approximately 5 cm proximal to the superior margin of the tumour, preserving a 2-3 cm-wide gastric channel along the lesser curvature. A side-to-side gastrojejunostomy is constructed between the posterior wall of the proximal gastric segment and the antimesenteric border of the jejunum 5-10 cm distal to the ligament of Treitz, via an antecolic route, in an isoperistaltic orientation. The common enterotomy is closed with a linear stapler or hand-sewn sutures.
Procedure: stomach-partitioning gastrojejunostomy
Participants undergo laparoscopic conventional gastrojejunostomy. A side-to-side anastomosis is constructed via an antecolic route between the most dependent portion of the greater curvature of the stomach and the proximal jejunum 5-10 cm distal to the ligament of Treitz, in an isoperistaltic orientation. The common enterotomy is closed with a linear stapler or hand-sewn sutures.
Procedure: conventional gastrojejunostomy
At the junction of the gastric body and the antrum, or about 5cm from the upper edge of the tumor, a straight-line cutting closure device was used to cut off part of the gastric body from the greater curvature of the stomach to form a partition, and a 2-3cm wide gastric body near the lesser curvature was retained. A hole was made in the greater curvature of the posterior gastric wall at the proximal end of the septum, and a hole was made in the jejunum-to-mesenteric margin 5-10 cm from the Treitz ligament. A linear cutting closure device was placed through the transverse colon. The greater curvature-jejunum side-to-side anastomosis of the posterior gastric wall with pro-peristalsis or anti-peristalsis was performed, and the common opening was closed by using a linear cutting closure device or suture.
Also known as: Conventional gastrojejunostomy
The lowest point of the greater curvature of the stomach and the proximal jejunum 5-10 cm away from the Treitz ligament were subjected to side-to-side anastomosis of peristaltic or anti-peristaltic using a linear cutter before the transverse colon, and the common opening was closed using a linear cutter or suture.
Incidence of delayed gastric emptying（DGE）
Delayed gastric emptying (DGE) is defined as impaired progression of oral intake, persistent or recurrent vomiting, abdominal distension, or prolonged or recurrent need for nasogastric tube (NGT) decompression, after mechanical causes (anastomotic stenosis or oedema, intestinal kinking or torsion, afferent or efferent limb obstruction) and other postoperative complications (postoperative ileus, anastomotic leakage, intra-abdominal infection, bleeding, tumour progression) have been considered and excluded where clinically appropriate. Severity is graded according to criteria adapted from the International Study Group of Pancreatic Surgery (ISGPS).
Time frame: Within 30 days after surgery
Time to postoperative gastrointestinal functional recovery
Time from surgery to the first occurrence of both passage of flatus and tolerance of a semi-liquid diet without vomiting or need for nasogastric tube decompression.
Time frame: Within 30 days after surgery
Nutritional status
Nutritional status assessed by the Patient-Generated Subjective Global Assessment (PG-SGA) score. PG-SGA assessment table contains seven aspects, which are divided into two parts : the patient self-assessment part ( A score ) and the medical staff assessment part ( B + C + D score ). The total score is obtained by adding the two parts.
Time frame: Baseline; 1, 2 and 4 weeks after surgery; before first postoperative systemic therapy
Health-related quality of life
Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the gastric cancer-specific module QLQ-STO22. Scores are standardised to a 0-100 scale.
Time frame: Baseline; 1, 2 and 4 weeks after surgery; before first postoperative systemic therapy
Incidence of early postoperative complications
Proportion of participants experiencing any postoperative complication graded Clavien-Dindo grade II or above, or any adverse event graded CTCAE v5.0 grade 2 or above, within 30 days after surgery.
Time frame: Within 30 days after surgery
Incidence of late postoperative complications
Proportion of participants experiencing any postoperative complication occurring from 30 days to 12 months after surgery.
Time frame: From 30 days to 12 months after surgery
Incidence of anastomotic complications
Proportion of participants experiencing anastomotic leakage, anastomotic stenosis, or anastomotic bleeding.
Time frame: Within 12 months after surgery
Postoperative mortality
Proportion of participants who die from any cause within 30 days and within 90 days after surgery.
Time frame: 30 days and 90 days after surgery
Initiation of subsequent systemic therapy
Proportion of participants initiating systemic anticancer therapy after surgery, and time from surgery to initiation.
Time frame: Within 12 months after surgery
Overall survival (OS)
Overall survival, defined as the time from surgery to death from any cause; participants alive at the prespecified analysis time point are censored at the date of last follow-up.
Time frame: Up to 12 months after surgery
Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication may be made available by the corresponding author upon reasonable request. Requests will be subject to approval by the principal investigator and the institutional ethics committee, compliance with applicable institutional and regulatory requirements, and execution of a data-sharing agreement.
Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.
Of 356 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 66. This study's planned 27 months is below that.
Counting every sponsor, half of 367 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jan 2028 → Jan 2029 and completion Jan 2029 → Mar 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (GO-PART Study, KLASS 16)
Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (GO-PART Study, KLASS 16)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangxi Medical University